WASHINGTON - Gilead Sciences Inc. said Monday that its experimental anti-coronavirus drug remdesivir will be supplied to the governments of developed countries at what it sees as an affordable price of $2,340 per patient for a typical five-day treatment course.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
